Results 41 to 50 of about 580 (106)
Acta Pharmaceutica Sinica B, 2020 Repurposing small molecule drugs and drug candidates is considered as a promising approach to revolutionise the treatment of snakebite envenoming. In this study, we investigated the inhibiting effects of the small molecules varespladib (nonspecific ...
Chunfang Xie +6 more
doaj +1 more source
BMJ Open, 2022 Introduction Inflammation is emerging as an important risk factor for atherosclerotic cardiovascular disease and has been a recent target for many novel therapeutic agents.
George A Wells +9 more
doaj +1 more source
Pharmaceuticals, 2023 Quercetin derivatives have already shown their anti-inflammatory potential, inhibiting essential enzymes involved in this process. Among diverse pro-inflammatory toxins from snake venoms, phospholipase A2 is one of the most abundant in some species, such
Mariana Novo Belchor +8 more
doaj +1 more source
Clinical management of snakebite envenoming: Future perspectives
Toxicon: X, 2021 Snakebite envenoming is a major cause of morbidity and mortality in rural communities throughout the tropics. Generally, the main clinical features of snakebites are local swelling, tissue necrosis, shock, spontaneous systemic hemorrhage, incoagulable ...
Muhammad Hamza +6 more
doaj +1 more source
The Urgent Need to Develop Novel Strategies for the Diagnosis and Treatment of Snakebites
Toxins, 2019 Snakebite envenoming (SBE) is a priority neglected tropical disease, which kills in excess of 100,000 people per year. Additionally, many millions of survivors also suffer through disabilities and long-term health consequences. The only treatment for SBE,
Harry F. Williams +6 more
doaj +1 more source
Mediators of Inflammation, 2021 Introduction and Hypothesis. The role of inflammation is widely recognized in the pathogenesis of coronary artery disease. Research on animal models had shown the potential benefits of targeting specific inflammatory pathways.
Ivan Wudexi +4 more
doaj +1 more source
Учёные записки Санкт-Петербургского государственного медицинского университета им. Акад. И.П. ПавловаSnake venoms have long been the subject of research in order to obtain new antitumor compounds. Snake secretory phospholipase A2 has cytotoxic properties that are realized through different mechanisms depending on the enzyme structure and cell type. HeLa
M. A. Solovyeva +5 more
doaj +1 more source
Recent Advances in Next Generation Snakebite Antivenoms
Tropical Medicine and Infectious Disease, 2018 With the inclusion of snakebite envenoming on the World Health Organization’s list of Neglected Tropical Diseases, an incentive has been established to promote research and development effort in novel snakebite antivenom therapies.
Cecilie Knudsen, Andreas H. Laustsen
doaj +1 more source
A-002 (Varespladib), a phospholipase A2 inhibitor, reduces atherosclerosis in guinea pigs
BMC Cardiovascular Disorders, 2009 Background The association of elevated serum levels of secretory phospholipase A2 (sPLA2) in patients with cardiovascular disease and their presence in atherosclerotic lesions suggest the participation of sPLA2 enzymes in this disease.
Fraser Heather +5 more
doaj +1 more source
Scientific Reports, 2019 The World Health Organization recently listed snakebite envenoming as a Neglected Tropical Disease, proposing strategies to significantly reduce the global burden of this complex pathology by 2030.
Guilherme H. M. Salvador +7 more
semanticscholar +1 more source